Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader - Wikidata - awgldk - TriplyDB

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

http://www.wikidata.org/entity/Q35178385

about

Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer.Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.

P2860

Q36088779-114CC6FA-01D6-4F54-9039-1BF05AC77CD3 Q36784269-1B7D08C7-AE63-40B0-8F85-A2BCBA17E4C0 Q37136745-10EA7CB0-761D-44D4-B776-8F7CFA732606 Q38907580-85EF17F4-7F3A-4A1D-A1EB-201048A33C8D Q39656587-AEDAB514-9E1D-432D-ADB3-383D048563F7 Q40409656-6938E4FF-64AC-4DF2-9C40-C3BF5F06D4A5 Q47732227-6375635C-B275-4BEB-90EA-D29E2E56DB88 Q51311647-C610C517-C4A1-4C80-9D73-D47A27EF1906 Q55069738-CF3F5810-D9B7-4B24-9066-315CDE2C642F Q55379548-64D57F66-2400-4BDC-8E99-103EEFE6F068

P2860

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

http://www.wikidata.org/entity/Q35178385

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@ast

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@en

type

label

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@ast

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@en

prefLabel

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@ast

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@en

P1433

Q35178385-37292FA7-E479-40DA-A60A-5089081FF324

P1476

Q35178385-B5F12768-A0EE-476F-9A8B-8BB98555F945

P2093

Q35178385-34DCB6D0-290E-4EA7-BCDB-B9145D5D87AA

Q35178385-73D86532-DEF6-4504-A62E-F5F0D50CD2C8

Q35178385-81BA83B3-DA3B-4E2D-BE04-B34D81CCD429

Q35178385-CD5D8CA6-120C-4CD1-910F-17796617B65D

Q35178385-DF079D35-1E0F-42BC-BD04-F64EF54867A2

Q35178385-FD5EE2EE-7489-4E49-83B7-C567EE9E3AC0

P2860

Q35178385-0CFEB99D-148A-4355-AA1A-3278FA2E6B0B

Q35178385-0F865A18-96C8-4E5A-B210-06CFB1803C50

Q35178385-1250E00E-6EBD-44CF-97A5-AC1A26BB5B77

Q35178385-16D59937-4556-4006-82EF-72C0A11C7E7B

Q35178385-24970136-2340-415D-8DAF-37F14A963A66

Q35178385-326F2CDF-093E-4224-B5F2-B11B63FB24BB

Q35178385-3331F5AE-908D-48BB-A3FA-78D56EAA4A7D

Q35178385-3C9C82C8-EE3E-4946-9909-E9A823AAA898

Q35178385-4A70325B-03FF-4CD6-91BB-36D5E15B3807

Q35178385-528ECCF4-C277-4B5D-ACDF-A4D6A08C5F4D

P304

Q35178385-2C7A4DEB-383E-4808-A1C5-40C20B22E987

P31

Q35178385-C601CD71-DC18-4469-A539-B999FDB64E23

P356

Q35178385-4B59E811-8D9B-4D16-B5B7-A10036008F23

P407

Q35178385-681907F0-B2B6-43F8-A3DB-54173844D190

P433

Q35178385-BB04DC30-7D3E-46F2-B6B1-5D63D9F04927

P478

Q35178385-45BDA54F-0785-4494-B97F-DD62B832F0C4

P50

Q35178385-77B2C6C4-708B-40E4-A40E-8D774A9626FD

P577

Q35178385-947311F4-D310-413A-B196-74BD860CF197

P5875

Q35178385-279FB3D9-55FB-48B7-85EE-F723DD7C2C55

P698

Q35178385-19435216-1443-44E3-A16F-6F2741B3D931

P932

Q35178385-4196E698-5FE7-4F08-8496-26D3D906A515

P356

1078-0432.CCR-14-1178

P1433

Clinical Cancer Research

P1476

Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader

@en

P2093

Alicia K Leece

http://www.w3.org/2001/XMLSchema#string

Neil Vasdev

http://www.w3.org/2001/XMLSchema#string

Pedram Heidari

http://www.w3.org/2001/XMLSchema#string

Shadi A Esfahani

http://www.w3.org/2001/XMLSchema#string

Timothy M Shoup

http://www.w3.org/2001/XMLSchema#string

Umar Mahmood

http://www.w3.org/2001/XMLSchema#string

P2860

Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol.

Fulvestrant (Faslodex) -- how to make a good drug better.

18F-Fluoroestradiol.

P304

1340-1347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1178

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271222251

http://www.w3.org/2001/XMLSchema#string

P698

25609068

http://www.w3.org/2001/XMLSchema#string

P932

4359957

http://www.w3.org/2001/XMLSchema#string